Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CLTCL1
REST API REST API
Homo sapiens
CLTCL1 is differentially expressed in 206 experiments: 83 organism parts: testis, skeletal muscle, ... (81 more);, 135 disease states: normal, acute promyelocytic leukemia, ... (133 more);, 69 cell types 184 cell lines 30 compound treatments and 64 other conditions.
Synonyms CLTCL, CLTD, CHC22, CLH22
Orthologs ENSCING00000009806 (Ciona intestinalis)   CLTCL1 (3 of 3) (Danio rerio)   CLTCL1 (Gallus gallus)   CHC1 (Saccharomyces cerevisiae)   ENSCING00000001739 (Ciona intestinalis)   CLTCL1 (1 of 3) (Danio rerio)   CLTCL1 (2 of 3) (Danio rerio)   Chc (Drosophila melanogaster)   LOC100492311 (Xenopus laevis)   CLTCL1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term clathrin coat of trans-Golgi network vesicle, clathrin coat of coated pit, protein binding, membrane, clathrin-coated vesicle, intracellular protein transport, structural molecule activity, receptor-mediated endocytosis, signal transducer activity, vesicle-mediated transport, coated pit, anatomical structure morphogenesis, spindle, coated vesicle, mitosis, cytoplasmic vesicle, trans-Golgi network, signal transduction, cytoplasmic vesicle membrane, positive regulation of glucose import
InterPro Term Clathrin_H-chain_propeller_rpt, Clathrin_H-chain/VPS_repeat, Clathrin_heavy_chain, Clathrin_H-chain_linker_core
UniProt Accession P53675, F5H5N6
Search EB-eye ENSG00000070371
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-MEXP-433, E-GEOD-7540, E-GEOD-3526, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-19397, E-GEOD-2450, ... (28 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
HCC1954
2
E-GEOD-29119, E-MTAB-37
BT-474
2
E-GEOD-5823, E-GEOD-3529
HL-60
1
2
E-GEOD-5258, E-GEOD-24147, E-MTAB-37
NALM6
1
E-MTAB-37
NCIH630
1
E-MTAB-37
178 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-4219, E-GEOD-20677, ... (37 experiments)

Factor Value U/D Experiments
CD34+
2
E-AFMX-5, E-TABM-145
M1 macrophage
1
E-GEOD-5099
centroblast
1
E-GEOD-15271
white blood cell
1
E-GEOD-2006
T-ALL
1
E-GEOD-19069
breast cancer
1
E-GEOD-29119
63 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-GEOD-1577, E-MEXP-2069, ... (37 experiments)

Factor Value U/D Experiments
Duchenne muscular dystrophy
2
E-GEOD-3307, E-GEOD-1004
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
acute promyelocytic leukemia
1
2
E-MTAB-62, E-GEOD-995, E-GEOD-1729
Breast adenocarcinoma
1
E-MTAB-62
NDV
1
E-GEOD-18791
129 more value(s).


Compound treatment

studied in E-GEOD-15205, E-TABM-782, E-GEOD-5824, E-TABM-868, E-GEOD-5099, ... (19 experiments)

Factor Value U/D Experiments
none
4
6
E-TABM-782, E-TABM-868, E-GEOD-412, E-GEOD-5824, E-GEOD-2649, ... (10 experiments)
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
unknown
1
E-GEOD-7307
NaOH
1
E-MEXP-2590
doxycycline
1
E-GEOD-2624
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
24 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21589, E-GEOD-16363, E-GEOD-19665 ... (5 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-3140, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MEXP-1482

Genotype
studied in E-TABM-763, E-GEOD-1923, E-GEOD-2292, E-TABM-321, E-TABM-868, ... (6 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-MEXP-1446, E-GEOD-9764, E-GEOD-10315, ... (6 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-TABM-15, ... (27 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-17400

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-22541

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-7114

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

RNAi
studied in E-GEOD-12438, E-GEOD-3697, E-MEXP-1857, E-MEXP-1315

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-7307

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-19246, E-GEOD-13818

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-TABM-147

Tumor size
studied in E-GEOD-6532

Processing time: 0.303 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM